tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VNDA Stock Latest News

Vanda Pharmaceuticals Advances Dry Eye Treatment with VSJ-110 Study
Company AnnouncementsVanda Pharmaceuticals Advances Dry Eye Treatment with VSJ-110 Study
24m ago
VNDA
Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment
PremiumCompany Announcements
Vanda Pharmaceuticals Completes Key Bioequivalence Study for Schizophrenia and Bipolar Disorder Treatment
5h ago
VNDA
VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
VNDA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12h ago
VNDA
Vanda’s FDA Agreement Boosts Buy Rating with Expedited Drug Reviews
PremiumRatings
Vanda’s FDA Agreement Boosts Buy Rating with Expedited Drug Reviews
25d ago
VNDA
Vanda Pharmaceuticals Reaches Agreement with FDA
PremiumCompany Announcements
Vanda Pharmaceuticals Reaches Agreement with FDA
26d ago
8K
VNDA
Vanda Pharmaceuticals, FDA agree to resolve disputes on Hetlioz and tradipitant
PremiumThe FlyVanda Pharmaceuticals, FDA agree to resolve disputes on Hetlioz and tradipitant
26d ago
VNDA
Vanda Pharmaceuticals’ Hetlioz meets primary endpoints in insomnia study
Premium
The Fly
Vanda Pharmaceuticals’ Hetlioz meets primary endpoints in insomnia study
1M ago
VNDA
Vanda’s Promising Pipeline and Strategic Advancements Drive Buy Rating
Premium
Ratings
Vanda’s Promising Pipeline and Strategic Advancements Drive Buy Rating
2M ago
VNDA
Vanda Pharmaceuticals’ VGT-1849B granted Orphan Drug designation
PremiumThe Fly
Vanda Pharmaceuticals’ VGT-1849B granted Orphan Drug designation
2M ago
VNDA
Vanda Pharmaceuticals treatment of polycythemia vera granted orphan designation
PremiumThe Fly
Vanda Pharmaceuticals treatment of polycythemia vera granted orphan designation
2M ago
VNDA
Vanda seeks FDA Commissioner review of Hetlioz generic ruling
PremiumThe Fly
Vanda seeks FDA Commissioner review of Hetlioz generic ruling
2M ago
VNDA
Vanda Pharmaceuticals’ Legal Victory and Potential HETLIOZ Approval Boosts Buy Rating
PremiumRatings
Vanda Pharmaceuticals’ Legal Victory and Potential HETLIOZ Approval Boosts Buy Rating
2M ago
VNDA
Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability
PremiumThe FlyVanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability
2M ago
VNDA
Strong Buy Rating for Vanda Pharmaceuticals Driven by Growth in Key Product Lines and Promising FDA Decision
Premium
Ratings
Strong Buy Rating for Vanda Pharmaceuticals Driven by Growth in Key Product Lines and Promising FDA Decision
3M ago
VNDA
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges
3M ago
VNDA
Vanda Pharmaceuticals Reports Q2 2025 Financial Results
PremiumCompany Announcements
Vanda Pharmaceuticals Reports Q2 2025 Financial Results
3M ago
VNDA
Vanda Pharmaceuticals reports Q2 EPS (46c) vs. (8c) last year
PremiumThe Fly
Vanda Pharmaceuticals reports Q2 EPS (46c) vs. (8c) last year
3M ago
VNDA
Vanda Pharmaceuticals still sees 2025 revenue $210M-$250M, consensus $227.71M
PremiumThe Fly
Vanda Pharmaceuticals still sees 2025 revenue $210M-$250M, consensus $227.71M
3M ago
VNDA
Vanda Pharmaceuticals Completes Key Study on Gastroparesis Treatment
PremiumCompany Announcements
Vanda Pharmaceuticals Completes Key Study on Gastroparesis Treatment
3M ago
VNDA
Vanda Pharmaceuticals (VNDA) Q2 Earnings Cheat Sheet
PremiumPre-EarningsVanda Pharmaceuticals (VNDA) Q2 Earnings Cheat Sheet
3M ago
VNDA
Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies
Premium
Company Announcements
Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies
3M ago
VNDA
Vanda Pharmaceuticals doses first patient in trial of VCA-894A
Premium
The Fly
Vanda Pharmaceuticals doses first patient in trial of VCA-894A
5M ago
VNDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >